TScan Therapeutics, Inc. is a biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment, including hematologic malignancies and solid tumors. Additionally, the company focuses on creating vaccines for diseases such as SARS-CoV-2. TScan has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to identify new cancer antigens.